Solana Company (HSDT) — formerly Helius Medical Technologies and now a publicly listed digital asset treasury and infrastructure firm providing institutional access to the Solana ecosystem — saw its shares decline 5.73% in Monday's session, falling to $1.81 from a prior close of $1.92. The move extended a multi-week downtrend and reflected renewed selling in Solana, the digital asset that underpins the company's treasury strategy and balance sheet.
The primary driver behind the stock's decline was a sharp pullback in Solana. SOL traded down to roughly $82.37 on November 10, its lowest level in about four weeks, and has now shed more than 22% over the trailing 28 days. Because HSDT is structured to maximize SOL per share — holding a Solana-heavy treasury, operating staking and validator infrastructure, and generating yield from staking rewards — its equity trades as a leveraged proxy for the token itself. When SOL falls, the mark-to-market value of the company's digital asset holdings declines in tandem, directly compressing the stock.
Additional selling pressure stemmed from sustained outflows in U.S. spot Solana exchange-traded funds, a signal that institutional investors have been trimming Solana-linked exposure rather than buying the dip. The redemptions compounded the impact of large on-chain transfers of SOL to centralized exchanges, which traders interpreted as potential profit-taking. Notably, the decline in HSDT occurred even as major U.S. equity indices rallied, highlighting that the move was driven by crypto-sector dynamics rather than broad risk-off sentiment.
Turnover in HSDT has remained elevated relative to its historical average in recent sessions, consistent with heightened sensitivity to Solana's price swings. The stock continues to trade below both its 50-day and 200-day moving averages, and momentum indicators remain in bearish territory, leaving shares without a clear technical floor. The move also aligned with weakness across the digital asset treasury cohort, which tends to fall more sharply than the underlying tokens when risk appetite cools.
Investors now turn their attention to the company's third-quarter operating results, scheduled for release after the market close on November 11. Given the firm's heavy exposure to Solana, the report is likely to reflect mark-to-market swings tied to the token's recent decline, alongside updates on staking yields, validator infrastructure, and its Asia-Pacific expansion. Key uncertainties include the trajectory of SOL, the pace of ETF flows, and the company's liquidity position relative to its digital asset holdings. Until Solana stabilizes, HSDT is likely to remain volatile and closely correlated with the underlying token.
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots spanning thousands of tickers. Only the strongest performers under current market conditions are featured, with bots distinguished by strategy, timeframe, performance metrics, and traded symbols. For traders monitoring volatility in names like HSDT, exploring these automated strategies can offer additional perspective on how data-driven systems are positioning in real time.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HSDT saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 75 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
HSDT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HSDT crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HSDT entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where HSDT advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
HSDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. HSDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.688) is normal, around the industry mean (2.412). P/E Ratio (0.010) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.270) among similar stocks. P/S Ratio (11.574) is also within normal values, averaging (15.694).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a medical technology company focused on neurological wellness
Industry InvestmentManagers